Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — Q3 2024 Earnings Presentation
21 slides from Tarsus Pharmaceuticals's earnings presentation, Nov 13, 2024
Slide 1: Third Quarter 2024 Financial Results Conference Call
Tarsus Pharmaceuticals Third Quarter 2024 Financial Results Conference Call November 13, 2024
Slide 2: Today's Speakers
Today’s Speakers Bobak Azamian, Aziz Mottiwala Sesha Neervannan, Jeff Farrow M.D., Ph.D. Ph.D. Chief Commercial Chief Financial Officer Chief Executive Officer Chief Operating Officer and Chief Strategy Officer and Chairman Officer 2 © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations about future events that we believe
Slide 4: Tarsus: Creating One of the Largest Categories in Eye Care
Tarsus: Creating One of the Largest Categories in Eye Care Exceptional growth and high-value payer coverage – $48.1M in Q3 2024 XDEMVY net product sales – Broad commercial and Medicare coverage now extends to >80% of covered lives Broad and increasing depth of ECP adoption – >13,000 ECPs started pat
Slide 5: XDEMVY: First Pharmacologic Treatment to Demonstrate Groundbreaking Improvements in MGD & Patient Symptoms
XDEMVY: First Pharmacologic Treatment to Demonstrate Groundbreaking Improvements in Objective Measures of MGD & Patient Symptoms Combined data1 in patients with DB and Meibomian Gland Disease demonstrated statistically significant and clinically meaningful improvements in objective measures and pati
Slide 6: Launched "Your Mitey Problem" Dynamic Television Campaign
Launched “Your Mitey Problem” Dynamic Television Campaign • Creative and memorable visuals to highlight damaging impact of the disease • Support patients in their journey and understanding of Demodex blepharitis • Launched on connected TV (CTV) platforms with plans to expand into network TV The camp
Slide 7: Strengthened Tarsus Leadership and Position in Eye Care
Strengthened Tarsus Leadership and Position in Eye Care Elizabeth Yeu, M.D., Kate Goodrich, M.D., MHS, Chief Medical Officer Board Member • Distinguished ophthalmologist with • Currently serves as the Chief more than two decades of Medical Officer of Humana Inc. experience • Former Chief Medical Off
Slide 8: XDEMVY: An Eye Care Launch Unlike Any Other
XDEMVY®: An Eye Care Launch Unlike Any Other $48.1 million in Q3 net product sales Driving strong demand • Delivered more than 41,400 bottles to patients • Accelerated ECP adoption: >13,000 prescribing with >70% prescribing to multiple patients4 ~25 Million1,2 High-value proposition • Durable and ro
Slide 9: Fully Deployed Sales Force is Driving Depth of Prescribing
Fully Deployed Sales Force is Driving Depth of Prescribing and Increased Utilization Across All DB Patient Segments Expanded sales force from approximately 100 to 150 at the end of the third quarter >13,0001 >70% XDEMVY Prescribers writing multiple times Increasing number of ECPs who prescribe XDEMV
Slide 10: XDEMVY Prescribing ECPs Surveyed Expected to Increase Utilization
XDEMVY Prescribing ECPs Surveyed Expected to Increase Utilization Significantly in Additional DB Patient Segments Additional Demodex Blepharitis Segments Dry Eye Cataracts Contact Lens with DB with DB with DB ~40% of ECPs Currently Prescribing XDEMVY Across Each Additional Segment 90%+ of Respondent
Slide 11: "Your Mitey Problem" Television Campaign
“Your Mitey Problem” Television Campaign • Patients identify with the campaign because it’s educational and motivating • Meaningful impact on sales expected in 2025 with possible expansion into network TV View TV spot at www.xdemvy.com 11 © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 12: Demodex Blepharitis is a Potential $1B+ Opportunity
Demodex Blepharitis is a Potential $1B+ Opportunity OPPORTUNITY 1.5M 1.2M 2.2M 2.3M 1.5M ~9M Patients with Demodex Proactively seeking Dry Eye Rx patients Cataract patients Contact lens MGD patients blepharitis (DB) treatment for DB or with DB1,3,4,5 with DB1,3,6 patients with DB1,2,3 complementary
Slide 13: XDEMVY: First Pharmacologic Treatment to Demonstrate Groundbreaking Improvements in MGD & Patient Symptoms
XDEMVY: First Pharmacologic Treatment to Demonstrate Groundbreaking Improvements in Objective Measures of MGD & Patient Symptoms Combined data1 in patients with DB and Meibomian Gland Disease demonstrated statistically significant and clinically meaningful improvements in objective measures and pati
Slide 14: XDEMVY Demonstrated Significant Improvement in Objective Measure of Meibomian Gland Disease
XDEMVY Demonstrated Statistically Significant and Clinically Meaningful Improvement in Objective Measure of Meibomian Gland Disease Analyses of Ersa and Rhea Trials in Patients with Demodex blepharitis and Meibomian Gland Diseasea • At Day 43, Lotilaner 0.25% showed a 51% improvement in number of gl
Slide 15: XDEMVY Improvements in Patient Symptoms – Fluctuating Vision and Itching
XDEMVY Demonstrated Statistically Significant and Clinically Meaningful Improvements in Patient Symptoms – Fluctuating Vision and Itching Analyses of Ersa and Rhea Trials in Patients with Demodex blepharitis and Meibomian Gland Diseasea • At Day 43, Lotilaner 0.25% showed a 52% improvement in Fluctu
Slide 16: A Category-Creating Pipeline With Near-Term Catalysts
A Category-Creating Pipeline With Near-Term Catalysts Tarsus Product Portfolio Product Upcoming Indication Formulation Preclinical Phase 1 Phase 2 Phase 3 Marketed Candidate Catalyst XDEMVY Demodex blepharitis (US) Eye drop Potential Approval in TP-03 Demodex blepharitis (EU) Eye drop Evaluating pre
Slide 17: Third Quarter 2024 Financial Results
Third Quarter 2024 Financial Results XDEMVY: On-track to potentially be one of the best launches in eye care XDEMVY Net Sales XDEMVY Bottles ($ in millions) Delivered to Patients (in thousands) $48.1 $40.8 37.0 41.4 $24.7 26.0 $13.1 15.0 $1.7 1.7 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q3 2023 Q4 20
Slide 18: Q&A
Q&A Bobak Azamian, Aziz Mottiwala Sesha Neervannan, Jeff Farrow Elizabeth Yeu, M.D. M.D., Ph.D. Ph.D. Chief Commercial Chief Financial Officer Chief Medical Officer Chief Executive Officer Chief Operating Officer and Chief Strategy Officer and Chairman Officer 18 © Tarsus Pharmaceuticals | For Inves
Slide 19: Closing Remarks
Closing Remarks Dp Tarsus
Slide 20: Appendix
Appendix Dp Tarsus
Slide 21: XDEMVY Improvements in Patient Symptoms – Redness and Burning
XDEMVY Demonstrated Statistically Significant and Clinically Meaningful Improvements in Patient Symptoms – Redness and Burning Analyses of Ersa and Rhea Trials in Patients with DB and MGDa • At Day 43, Lotilaner 0.25% showed a 57% improvement in Redness compared to baseline • At Day 43, Lotilaner 0.
Tarsus Pharmaceuticals — Q3 2024 Earnings Presentation on 6ix